Get the Stockscreener App
42.53
2.46%
1.02
After Hours:
42.90
0.37
+0.87%
Terns Pharmaceuticals Inc stock is traded at $42.53, with a volume of 1.95M.
It is up +2.46% in the last 24 hours and up +17.94% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$41.51
Open:
$42.05
24h Volume:
1.95M
Relative Volume:
0.69
Market Cap:
$4.63B
Revenue:
-
Net Income/Loss:
$-94.44M
P/E Ratio:
-41.21
EPS:
-1.032
Net Cash Flow:
$-77.99M
1W Performance:
+2.78%
1M Performance:
+17.94%
6M Performance:
+502.41%
1Y Performance:
+1,112%
1-Day Range:
$41.58
$43.00
1-Week Range:
$38.82
$43.00
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
42.53 | 4.51B | 0 | -94.44M | -77.99M | -1.032 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Leerink Partners | Outperform |
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
TERN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Portfolio Update: How does Terns Pharmaceuticals Inc score in quality rankingsMarket Rally & Low Risk Entry Point Tips - baoquankhu1.vn
A Look At Terns Pharmaceuticals (TERN) Valuation After Leerink Highlights Early TERN-701 CML Data - Yahoo Finance
15 Stocks with the Biggest Hedge Fund Momentum - Insider Monkey
Does Rising Hedge Fund Interest in Terns (TERN) Reveal a Deeper Bet on Single-Asset Biotech Risk? - Sahm
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug - Yahoo Finance
TERN Should I Buy - Intellectia AI
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences - The Manila Times
CEO Change: Will LDWY benefit from geopolitical trends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing - AOL.com
Nasdaq Moves: How does Terns Pharmaceuticals Inc score in quality rankingsQuarterly Portfolio Review & Consistent Return Investment Signals - baoquankhu1.vn
Commit To Buy Terns Pharmaceuticals At $30, Earn 34% Using Options - Nasdaq
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge - AOL.com
Terns Pharmaceuticals (NASDAQ:TERN) Stock Rating Upgraded by TD Cowen - Defense World
Terns Pharmaceuticals (NASDAQ:TERN) Raised to "Strong-Buy" at TD Cowen - MarketBeat
What are Terns Pharmaceuticals Inc.’s technical support levels2025 Trading Recap & Consistent Profit Focused Trading Strategies - mfd.ru
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing - The Globe and Mail
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing - The Motley Fool
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Bull Run: How does Terns Pharmaceuticals Inc score in quality rankings2025 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Terns (TERN) CEO sells 14,583 shares after option exercise - Stock Titan
Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high? - MSN
Can Terns Pharmaceuticals Inc. be the next market leaderJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
Terns Pharmaceuticals (NASDAQ:TERN) Upgraded at Wall Street Zen - MarketBeat
Block Trades: Can Terns Pharmaceuticals Inc be the next market leader2025 Technical Patterns & Growth Focused Entry Reports - baoquankhu1.vn
Vivo Capital funds disclose minority stakes in Terns Pharmaceuticals (TERN) on 13G/A - Stock Titan
Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target - marketscreener.com
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating By Investing.com - Investing.com Canada
Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - MarketBeat
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating - Investing.com
VIX Spike: What are Terns Pharmaceuticals Incs technical support levels2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
Certain Stock Options of Terns Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? - sharewise.com
Terns Pharmaceuticals, Inc. $TERN Stock Position Increased by AlphaQuest LLC - MarketBeat
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update - Sahm
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Terns Pharmaceuticals (TERN) Valuation Check After Expanded Global Rights To TERN-701 - Yahoo Finance
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule - TradingView
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders - Sahm
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment - Finviz
Terns Pharmaceuticals patent discloses GIPR antagonists - bioworld.com
What is Terns Pharmaceuticals Inc. s 5 year growth outlook2025 Historical Comparison & Daily Profit Maximizing Trade Tips - mfd.ru
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):